Head and Neck (RTOG 1016): HPV Associated Oropharynx Cancer
A Randomized Phase III Trial of Radiotherapy Plus Cetuximab versus chemotherapy in HPV-Associated Oropharynx Cancer.
Head and Neck
Must be positive for p16 as determined by central lab prior to study entry. Clinical stage T1-2 N2a-N3 or T3-4 any N w/ no distant metastasis. Ineligible if gross total excision of both primary and nodal disease is performed. Cancers from the oral cavity site are not eligible. Carcinoma of the neck of unknown primary site origin are not eligible.